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Translational oncologyDespite intense efforts, the socioeconomic burden of cancer remains unacceptably high and treatment
advances for many common cancers have been limited, suggesting a need for a new approach to drug
development. One issue central to this lack of progress is the heterogeneity and genetic complexity of
many tumours. This results in considerable variability in therapeutic response and requires knowledge
of the molecular proﬁle of the tumour to guide appropriate treatment selection for individual patients.
While recent advances in the molecular characterisation of different cancer types have the potential to
transform cancer treatment through precision medicine, such an approach presents a major economic
challenge for drug development, since novel targeted agents may only be suitable for a small cohort of
patients. Identifying the patients who would beneﬁt from individual therapies and recruiting sufﬁcient
numbers of patients with particular cancer subtypes into clinical trials is challenging, and will require1 44 634
euven.be
t-puig@
ordet.be
130 R. Stahel et al. / Cancer Treatment Reviews 41 (2015) 129–135collaborative efforts from research groups and industry in order to accelerate progress. A number of
molecular screening platforms have already been initiated across Europe, and it is hoped that these net-
works, along with future collaborations, will beneﬁt not only patients but also society through cost reduc-
tions as a result of more efﬁcient use of resources. This review discusses how current developments in
translational oncology may be applied in clinical practice in the future, assesses current programmes
for the molecular characterisation of cancer and describes possible collaborative approaches designed
to maximise the beneﬁts of translational science for patients with cancer.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
There is an urgent need for a new approach to drug develop-
ment for many common cancers, for which treatment progress
has been limited and the socioeconomic burden remains unaccept-
ably high. One issue that is central to the lack of progress in cancer
treatment is the heterogeneity and genetic complexity of many
tumours [1,2]. This leads to considerable variability in patients’
response to therapy and requires knowledge of the molecular pro-
ﬁle of an individual’s tumour to guide appropriate treatment selec-
tion. Nevertheless, signiﬁcant advances have been made in the
molecular characterisation of different cancer types in recent
years, which have the potential to transform treatment through
precision medicine [3–5]. It should be noted, however, that such
an approach presents a major economic challenge for drug devel-
opment, since novel targeted agents may only be suitable for a
small cohort of patients [2]. Identifying sufﬁcient numbers of
patients with rare genetic aberrations for enrolment into clinical
trials is a further obstacle. To overcome these challenges and max-
imise progress in the development of more effective cancer treat-
ments, collaborative efforts between academia and industry are
needed.
This review discusses how current developments in transla-
tional oncology may be applied in clinical practice in the coming
years, reviews current programmes for the molecular characterisa-
tion of cancer and describes possible collaborative approaches
designed to maximise the beneﬁts of translational science for
patients with cancer.Current challenges in translational oncology
Advances in genomic sequencing in recent years have facili-
tated the identiﬁcation of numerous new gene mutations or ampli-
ﬁcations that may be appropriate for genomic-driven drug
development [6]. For example, in breast cancer, genomic altera-
tions have been found to be focused primarily in PI3K/AKT/mam-
malian target of rapamycin (mTOR), human epidermal growth
factor receptor 2 (HER2), p53 and retinoblastoma tumour suppres-
sor pathways, suggesting the possibility of clustering several
genomic alternations into functional pathways [7]. However, these
ﬁndings and the results of other studies in different cancer types
undertaken over the last decade have revealed a highly complex
and heterogeneous genomic landscape [1,2,8–10].
Tumour heterogeneity is apparent in almost all tumour pheno-
types [11] and exists both between the tumours of patients with
the same histopathological cancer type [12] and within individual
tumours [13]. Somatic mutations occur throughout the genome
over time as a result of exposure to different external or internal
forces or carcinogens, with imprints of DNA damage to repair pro-
cesses affecting the development of cancer (Fig. 1) [14]. Mutation
signatures can differ depending on the length of exposure, leading
to alterations in drug response, and the number of mutations can
also vary considerably between patients and tumour types. Wholegenome sequencing may provide insight into the molecular mech-
anisms underlying these mutations [15,16], and the advent of
next-generation sequencing (NGS) has meant that such analysis
is now becoming available in academic hospitals. However, inter-
pretation of NGS ﬁndings is complex since the technique cannot
deﬁne the prevalence of particular mutations nor make any infer-
ence of their predictive values. Identiﬁcation of appropriate bio-
markers suitable for clinical use and their prognostic and
predictive values is also an issue, along with controlling for sample
heterogeneity and population-speciﬁc differences [6]. Initial stud-
ies also failed to take into account differences in mutation fre-
quency (between patients and tumour types), gene expression
level and replication time, resulting in spurious ﬁndings [17]. Con-
sequently, at present, the technology is generally only validated for
research.
Heterogeneity in cancer tumours creates a considerable chal-
lenge for the development of targeted therapy. In particular, driver
mutations responsible for growth and survival could well vary
between patients as a result of inter-tumour heterogeneity, while
intra-tumour heterogeneity may lead to the rapid development
of resistance to therapy due to genomic variability between cancer
cell clones [2,18]. The modest efﬁcacy many targeted agents exhi-
bit as a result of resistance development leads to poorer outcomes,
which limits the possibility of reimbursement, reducing the medi-
cal usefulness of some agents. Undertaking registration studies for
novel agents targeted at rare mutations is also problematic, since it
requires large-scale molecular screening in order to gain sufﬁcient
numbers of clinical trial subjects. When such agents are applied in
the clinic, they will similarly require testing for use in the few
patients with the rare mutation. The development of novel tar-
geted therapies should also take into account the pattern of other
mutations present, since cross-talk between mutated genes can
have a profound effect on the fate of the cell, determining whether
cell death or clonal expansion results [14]. Consequently, for some
mutations (e.g. PI3K), it may be more useful to consider activation
of the pathway rather than the mutation itself; however, the pos-
sibility of evaluating ‘pathway activation’ may be several years
away.
A number of strategies which aim to counteract tumour heter-
ogeneity are under consideration. For example, combining targeted
therapy and immunotherapy in patients with low levels of genetic
instability may overcome drug resistance and improve the long-
term efﬁcacy of treatment; studies are under way to identify
immune system markers in order to investigate this hypothesis
further [19]. The molecular mechanisms that drive diversity and
heterogeneity in cancer may also be targeted, with particular focus
on RNA as its sequence, degradation and structure can be altered
by RNA editing, which may change the tumour transcriptome
[20]. Approaches aimed at RNA may, therefore, be a potential
means of targeting the process that leads to genomic alterations
rather than the mutation itself. Additionally, tumour evolution
over time may be monitored though the use of liquid biopsies,
involving, for example, measurement of levels of circulating
tumour DNA (ctDNA) or circulating tumour cells (CTCs) [21–27].
Fig. 1. The role of the environment in evolutionary adaptation. Reproduced with permission from Yates and Campbell [14]. A multitude of environmental factors may shape
the evolutionary processes within a single cancer. Blue and purple bubbles represent successive cancer clones, the expansion of which is altered by directly mutagenic factors
(grey arrows) and non-mutagenic factors (black arrows).
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better reﬂection of tumour burden and estimation of outcome than
CTC count, and is also more sensitive [21,22,24]. Technology with
which to quantify ctDNA is rapidly evolving, though the applica-
tion of this measurement in clinical practice to monitor disease
progression and response to treatment requires trials to validate
its clinical beneﬁt.Fig. 2. Use of circulating tumour DNA (ctDNA) to monitor disease resistance to therapeut
and Tabernero [26]. Many patients with CRC develop resistance to drugs that target th
proliferation of rare tumour cells with mutations in the KRAS gene that allow them to su
grey line) by testing for the presence of KRASmutations in ctDNA derived from a patient’s
at an earlier stage of disease progression than can be achieved using standard technique
detection would allow treatment with a drug targeting an alternative pathway to be ini
harbour mutations conferring resistance to the second drug, and that these cells will, inCurrent programmes for the molecular characterisation of
cancer
Over the last decade, the molecular characterisation of different
cancers has revealed an increasing number of subtypes comprising
fewer and fewer patients, which creates a major obstacle to drug
development. Clinical trials involving patients with rare mutationsic agents in patients with colorectal cancer (CRC). Reproduced with permission Vilar
e epidermal growth factor receptor (EGFR). This resistance could be caused by the
rvive anti-EGFR therapy. These mutated cells can be detected and quantiﬁed (dark
blood. This ctDNA screening could allow the onset of drug resistance to be detected
s, which rely on imaging to look for enlarged tumour size and/or metastasis. Earlier
tiated sooner. However, it is likely that the tumour will also contain rare cells that
turn, become more prevalent (pale grey line).
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number of individuals that must be screened; this highlights an
urgent need for large collaborative networks. A number of initia-
tives have been developed to meet this requirement, the most well
established being in the gastrointestinal, lung and breast cancer
ﬁelds.
Gastrointestinal cancer
SPECTAcolor (Screening Patients for Efﬁcient Clinical Trials
Access) is a biomarker analysis platform developed by the Euro-
pean Organisation for the Research and Treatment of Cancer
(EORTC) for the genetic proﬁling of patients with advanced
colorectal cancer (CRC) [28]. The platform aims to improve access
to and reduce the cost of molecularly-driven clinical trials by cen-
tralising screening to improve quality control. A number of centres
across Europe are involved in the initiative, with the aim of
collecting data from 1000 patients per year. Patients enrolled in
SPECTAcolor receive molecular screening early in the course of
their disease (just after the development of metastases), and
assessments are repeated at 6-monthly intervals in order to assess
eligibility for different trials over time. The initial screening
included exome sequencing of over 250 genes, though testing is
likely to be expanded as investment in the programme increases
and science evolves. While trials are independent of the EORTC,
participating companies have been asked to adhere to certain stan-
dards; the use of a common infrastructure and umbrella protocols
may reduce start-up time and facilitate the efﬁcient running of tri-
als. Such standardisation could also avoid the need for the pre-
screening of trial centres, making the process more time and cost
efﬁcient. Seed money to start up and run SPECTAcolor for 5 years
was donated by Alliance Boots and future costs of running the plat-
form will be shared by pharmaceutical companies. The SPECTAcol-
or model is now being expanded to other tumour types, including
melanoma and brain and lung cancers (SPECTAmel, SPECTAbrain
and SPECTAlung, respectively; the last one in collaboration with
the European Thoracic Oncology Platform [ETOP – see below]).
Lung cancer
ETOP aims to promote exchange of knowledge and research in
the ﬁeld of thoracic malignancies as well as to sponsor or perform
clinical studies. Lungscape, a programme initiated by ETOP, was
developed to study the molecular landscape of non-small cell lung
cancer (NSCLC), to allow comprehensive clinico-pathological corre-
lations and to establish robust and standardised procedures for
molecular testing in clinical trials [29]. Lungscape will follow a
stepwise evolution, with step 1 involving retrospective analysis
of more than 2400 resected NSCLC cases with at least 3 years’
clinically annotated follow-up. Samples from patients with stage
IA–IIIB NSCLC have been collected, enabling the biomarkers to be
evaluated at different stages of disease. The ﬁrst biomarker inves-
tigated by Lungscape was anaplastic lymphoma kinase (ALK), and
subsequent testing will examine PIK3CA, MET, RANK/L and PD1/
PDL1, and will screen for about 200 cancer gene mutations by mul-
tiplex technology. The tissue biobank and database allow a number
of outcomes (e.g. overall survival [OS], progression-free survival
[PFS], relapse-free survival and time to relapse) and clinical param-
eters (e.g. performance status, gender and age) to be investigated
according to disease stage; the impact of different biomarkers on
risk of relapse can also be evaluated. Seventeen centres are cur-
rently involved in step 1. Each case submitted to the database is
reviewed to ensure that staging and tissue quality are appropriate.
Laboratory testing using ‘round robins’ and quality assurance pro-
cedures is performed locally when possible in order to empower
European centres with useful biomarker testing.Step 2 of Lungscape aims to progress this retrospective analy-
sis into a prospective study in patients with advanced disease,
with the primary endpoints being OS and/or PFS improvement
and treatment decided by molecular characterisation. In order
to move this concept forward collaboration between ETOP and
the EORTC has been established (SPECTAlung). Industry is being
approached to join this initiative, which will be expanded to other
thoracic malignancies. In addition to the very large mutation
platform, SPECTAlung, developed in collaboration with the Sanger
Institute, a master protocol is being developed to allow rapid
access to clinical trials for patients with molecularly deﬁned lung
cancer.
Breast cancer
The AURORA (Aiming to UndeRstand the mOlecular abeRrations
in metAstatic breast cancer) molecular screening platform is run by
the Breast International Group (BIG) and aims to make signiﬁcant
improvements in our understanding of the clonal evolution of
breast cancer [30]. The platform will enrol at least 1300 patients
with newly diagnosed metastatic breast cancer for whom tissue
is available from both the primary tumour and metastatic lesion.
Targeted gene sequencing of around 400 known cancer driver
genes will be performed on all samples by a central laboratory.
Patients with actionable and non-actionable mutations will then
be enrolled in a comprehensive follow-up programme and will
receive either new targeted agents in clinical trials or standard
therapies, with data being collected every 3–6 months to deter-
mine response and survival endpoints. Trials for patients enrolled
in AURORA will be ﬂexible, with some run by BIG and others by
independent companies.
Three phase II trials are already planned as part of the AURORA
programme, with patients being allocated to the appropriate study
according to the molecular status of their tumour. These studies
will involve patients with aberrations whose expected incidences
are 9% (Target 1), 1.5% (Target 2) and 25% (Target 3) (Fig. 3). A num-
ber of sister programmes to AURORA are also planned, which may
focus on the tumour microenvironment, drug resistance mecha-
nisms and use of ctDNA to monitor tumour evolution, though
funding for such studies is not yet secured.
While it is recognised that not all institutions will join AURORA,
it is hoped that most will enrol patients with aberrations with inci-
dences of <5% (e.g. HER2 mutations), since it is almost impossible
to run randomised trials in such cases without international collab-
oration. Around 30 centres are committed to joining the pro-
gramme at present. Each centre is pre-screened to ensure the
presence of a good pathology department and experience in phase
I/II trials. The molecular screening platform is funded by the Breast
Cancer Research Foundation and a number of European charities. It
is currently being tested in a feasibility study (n = 30) to ensure
that the biotracking works from a logistical viewpoint. Additional
funding will be sought from various sources in order to expand
the programme further.
A multicentre, molecular screening study undertaken in 18 cen-
tres across France involving 423 patients (SAFIR01/UNICANCER)
has recently provided evidence of the feasibility of personalised
medicine for metastatic breast cancer. In this initiative, targetable
genomic alterations were indentiﬁed in 46% of patients (most com-
monly PIK3CA, CCND1 and ﬁbroblast growth factor receptor
1[FGFR1]), providing the possibility of personalised therapy in
13% of individuals [31].
Challenges in implementing molecular screening platforms
Funding remains the principal barrier to the implementation of
molecular screening platforms. The platforms described above are
Fig. 3. Clinical trials in patients with breast cancer planned in the AURORA (Aiming to UndeRstand the mOlecular abeRrations in metAstatic breast cancer) programme
initiated by the Breast International Group (BIG).
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to expand, the programmes must attract industry funding, though
such investment will require evidence that molecular screening
will ultimately result in a more efﬁcient drug development process
and improved patient outcomes. Collaboration between academia
and industry will be pivotal to the implementation of future plat-
forms; however, this partnership presents challenges, such as
obtaining agreement on data sharing and intellectual property
rights (IPR). The optimal balance between centralisation and local
empowerment must also be considered; motivation can be an
issue if all services are centralised, particularly for pathologists
who play a key role in the molecular screening programmes. Nev-
ertheless, there is a need for processes to be standardised to ensure
quality control. The reproducibility of multiplex technology must
also be evaluated with care, since a large proportion of tumour het-
erogeneity can be due to variations in tissue handling [32]. A fur-
ther challenge for molecular screening platforms is that clinicians
may need encouragement to include their patients: few patients
ultimately take part in a trial (<10 for every 100 patients proposed)
yet paperwork must be completed for all potential participants.
Despite the challenges associated with their implementation,
molecular screening platforms should be considered to be the
way forward for future drug development, and the opportunity
to share ideas and experiences (including protocol development)
between programmes must be explored to maximise their poten-
tial. Clinical trials involving patients with rare mutations (e.g.
HER2) are almost impossible to conduct at a national level since
they require many thousands of patients to be screened. However,
coordination between platforms could enable key centres to be
involved in more than one programme, aiding enrolment in such
trials and potentially resulting in cost savings by using a common
protocol. Coordination between platforms may also help topromote the concept of molecular screening platforms to external
bodies to gain funding.
Optimising clinical trial design using translational oncology
The use of smarter, faster and better-targeted phase III clinical
trials can reduce cost and molecular screening platforms have
the ability to improve the efﬁciency of trial access. However, in
order to maximise the potential of translational oncology, appro-
priate trial designs must be used [33,34]. Regulators still require
new drugs to be tested in patients with and without the alteration
in a 2  2 design, which inevitably requires a large sample size.
However, a number of novel trial designs for assessing targeted
treatments using biomarkers have been proposed, which may
avoid the need for a 2  2 design (Fig. 4) [33]. Whatever study
design is used, investigators must ensure that trials are sufﬁciently
powered at the beginning for the question being asked, as sample
sizes vary considerably depending on the prevalence of the marker
and the hazard ratio required. Moreover, if assessment of the mar-
ker is biased due to poor assay sensitivity or speciﬁcity, even
greater sample sizes are needed [33].
Trialists setting up future studies will need to consider the most
appropriate strata to use carefully in order for credible estimates of
treatment effects to be made. Increasing knowledge of the inter-
patient, inter-tumour and intra-tumour heterogeneity of cancer
will continue to separate eligible populations, though clinical trials
can only be undertaken on the basis of aggregation of sufﬁciently
similar classes. A further challenge for the design of trials for tar-
geted agents is that regulators require such studies to show an
increase in OS, yet this is a demanding endpoint, and indirect
means of demonstrating improvement in OS are now needed.
Gaining regulatory approval for targeted agents for rare mutations
Fig. 4. Possible clinical trial designs for targeted therapy. Reproduced with permission Hoering et al. [33].
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gain sufﬁcient numbers for a phase II trial, ethically no comparator
arm can be included and the sample sizes needed for a phase III
trial are prohibitive. Demonstration of a good response in two sep-
arate phase II trials followed by a randomised phase II study versus
chemotherapy may be a strategy that can overcome this issue and
may be acceptable to regulatory authorities. Consideration should
also be given to the use of ‘basket’ trials involving patients with the
same mutation in different tumour types. For tumours such as
breast cancer and CRC where patients respond to chemotherapy,
the use of patient-reported outcomes to demonstrate additional
beneﬁt from novel agents should be explored. In addition, it is pos-
sible that translational research may lead to the development of
new endpoints (e.g. CTCs and molecular imaging) that can measure
response early in the course of treatment, though prospective val-
idation of such endpoints is needed before their adoption in clinical
practice. The development of any new translational research tech-
niques should also consider protocol standardisation at an early
stage to avoid future problems in their integration into novel trial
endpoints.
In recent years, the Food and Drug Administration in the USA
has used breakthrough designation status to expedite approval of
innovative new drugs that demonstrate signiﬁcant PFS or response
rate in a phase II trial. Such status is only granted if there are no
good alternative treatments and may be particularly beneﬁcial
for the development of targeted agents for rare mutations. The reg-
ulator may require evidence that a larger phase III comparative
trial is already under way at the time of accelerated approval.
Nevertheless, alternative endpoints will need to be considered
for approval in this setting, as OS improvement cannot be demon-
strated using evidence from a randomised study if the drug is
already on the market. A similar early approval process is under
discussion at the European Medicines Agency (EMA); however, dif-
ferences in healthcare funding between the USA and Europe may
be an issue in this regard.Models of collaboration in translational oncology
There is an urgent need for academia, pharmaceutical compa-
nies and regulatory authorities to work together in order tomaximise the beneﬁts of translational oncology for patients and
accelerate progress in drug development. The experiences of exist-
ing molecular screening platforms should also be shared in order to
identify best practice for future collaborative models. As a ﬁrst
step, oncology centres and networks must ensure that they have
standard procedures in place for biospecimen collection and use
in clinical trials, such as those recommended by BIG and the North
American Breast Cancer Group (NABCG), in order to minimise var-
iability and maximise results [34]. Ideally, central biobanking
should be under academic control and independent of industry,
but with a steering committee involving all parties in place to
determine how samples are used along with an efﬁcient tracking
system. Consideration should be given to the collection of blood
and tumour tissue from all patients in clinical trials for biomarker
discovery, with strict quality control policies being applied to sam-
ple collection, including procedures to ensure appropriate storage
and transportation [35].
One issue that remains an ongoing challenge to collaborative
efforts is ownership of data; negotiation of IPR and contracts in col-
laborative trials can result in considerable project delays and new
policies to manage licensing agreements are required [36]. As part
of these discussions, consideration must be given to whether
discoveries were part of the original protocol or later research pro-
jects, as well as to who has funded these projects. Pharmaceutical
companies must also appreciate that there needs to be incentives
for academia to be involved in trials. Standardising contracts may
help to avoid future IPR issues and ensure that trials are completed
in a time-efﬁcient manner, though agreements must include a pro-
tocol for what to do with left-over materials and specify the dura-
tion of sample storage. Material Transfer Agreements should also
be signed before any shipment of samples from the biobank. What-
ever the agreement in place, however, researchers and clinicians
owe it to society to extract the maximum knowledge from every
clinical trial, with data being made available to the entire scientiﬁc
community. Indeed, as the complexity of the data generated by
translational research increases, the pressure for academia and
industry to share data has intensiﬁed. While open access to data
from clinical trials may improve the quality of subsequent publica-
tions, it also generates scientiﬁc, statistical, ethical and legal con-
cerns, and could demotivate the investigators. Nevertheless, the
EMA committed to implementing a policy on proactive publication
R. Stahel et al. / Cancer Treatment Reviews 41 (2015) 129–135 135of all clinical trial data in January 2014 [37] and open access has
been mandatory in the USA since 2008.Consequently, all clinical
trials must move towards transparency, with the ultimate aim of
efﬁciently managing valuable resources and maximising the
potential clinical beneﬁt from the data gathered.
While collaborative models may be expected to lead to more
efﬁcient use of resources, additional developments may be needed
to expedite the drug development process further, including
improvements in access to clinical trials, advances in molecular
screening, clustering of genomic alterations according to pathways,
and collaborative trials between academia and industry that test
multiple drugs simultaneously [38].
Summary
Huge strides forward have been made in the understanding of
the molecular biology of cancer in recent years as a result of
advances in genomic analysis techniques. Progress has also been
made in the treatment of the disease, with many targeted therapies
becoming available. It is now clear from the results of molecular
research that cancer should not be considered as a single entity
but as a series of diverse diseases with an increasing number of
molecular subtypes within each tumour type. Identiﬁcation of
the patients who will beneﬁt from individual therapies and recruit-
ment of sufﬁcient numbers of individuals with particular tumour
subtypes into clinical trials is challenging, and will require collab-
orative efforts from research groups and industry in order to accel-
erate progress. A number of molecular screening platforms have
already been initiated across Europe. It is hoped that the experi-
ences gained from these networks can be used to identify best
practice for future collaborative models. This will beneﬁt not only
patients but also society due to a reduction in costs as a result of
more efﬁcient use of resources.
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